1077 related articles for article (PubMed ID: 27137146)
1. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
2. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
[TBL] [Abstract][Full Text] [Related]
3. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
4. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
5. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
6. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
7. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
10. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G; Xu E; Thipphawong J; Gupta SK
BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
14. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
15. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
16. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
17. Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Liranso T; Schwabe S; Nasser A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):69-79. PubMed ID: 34652564
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
19. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
Katz N; Sun S; Johnson F; Stauffer J
J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
[TBL] [Abstract][Full Text] [Related]
20. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
